US Animal Parasiticides Market

ID: MRFR/Agri/19199-HCR 128 Pages Snehal Singh Last Updated: September 10, 2026

US Animal Parasiticides Market Size, Share, Industry Trend & Analysis Research Report: By Type (Endoparasiticides, Ectoparasiticides, Antiparasitic Combination Products), By Animal Type (Livestock, Companion Animals, Aquatic Animals), By Formulation (Tablets, Injectables, Topicals, Orals, Powders) andBy Distribution Channel (Veterinary Clinics, Online Pharmacies, Retail Stores)- Forecast to 2035

US Animal Parasiticides Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.51%
2024 Market Size$ 1,606.5 Million
2025 Market Size$ 1,727.15 Million
2035 Market Size$ 3,563.7 Million
Key Players
Boehringer Ingelheim
Zoetis
Merck Animal Health
Bayer Animal Health
Elanco Animal Health
Virbac
Opportunities
  • Rising Pet Ownership
  • Increased Awareness of Animal Health
  • Regulatory Support for Animal Health Products
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Million)
      1. 4.1.1 Endoparasiticides
      2. 4.1.2 Ectoparasiticides
      3. 4.1.3 Antiparasitic Combination Products
    2. 4.2 Healthcare, BY Animal Type (USD Million)
      1. 4.2.1 Livestock
      2. 4.2.2 Companion Animals
      3. 4.2.3 Aquatic Animals
    3. 4.3 Healthcare, BY Formulation (USD Million)
      1. 4.3.1 Tablets
      2. 4.3.2 Injectables
      3. 4.3.3 Topicals
      4. 4.3.4 Orals
      5. 4.3.5 Powders
    4. 4.4 Healthcare, BY Distribution Channel (USD Million)
      1. 4.4.1 Veterinary Clinics
      2. 4.4.2 Online Pharmacies
      3. 4.4.3 Retail Stores
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Boehringer Ingelheim (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Zoetis (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck Animal Health (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer Animal Health (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Elanco Animal Health (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Virbac (FR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Ceva Santé Animale (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Dechra Pharmaceuticals (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY ANIMAL TYPE
    4. 6.4 US MARKET ANALYSIS BY FORMULATION
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 HEALTHCARE, BY FORMULATION, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Million)
    18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY FORMULATION, 2025-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Animal Parasiticides Market Segmentation

US Animal Parasiticides Market By Type (USD Million, 2025-2035)

  • Endoparasiticides
  • Ectoparasiticides
  • Antiparasitic Combination Products

US Animal Parasiticides Market By Animal Type (USD Million, 2025-2035)

  • Livestock
  • Companion Animals
  • Aquatic Animals

US Animal Parasiticides Market By Formulation (USD Million, 2025-2035)

  • Tablets
  • Injectables
  • Topicals
  • Orals
  • Powders

US Animal Parasiticides Market By Distribution Channel (USD Million, 2025-2035)

  • Veterinary Clinics
  • Online Pharmacies
  • Retail Stores
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.